Aardvark Therapeutics, Inc. — Form 8-K
Filed October 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
FDA lifted its clinical hold on ARD-101 (Aardvark's investigational drug for Prader-Willi Syndrome hyperphagia) on October 22, 2026, after the company completed ECG and cardiac sodium channel studies in healthy volunteers. The HERO Phase 3 trial and its open-label extension were paused in February 2026 following reversible ECG changes, and the FDA imposed a hold in May 2026; no cardiac events were observed at doses of 200–400 mg twice daily. Aardvark plans to resume clinical development pending further FDA alignment on trial design.
Why this rating
Clinical hold removal unblocks ~$163M company's lead asset; material de-risking, but efficacy data from terminated trial remains unproven and FDA re-engagement required before resumption.
Price action (we called it positive)
before filing · preread $3.95 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.